France Precision Oncology Market Size & Outlook, 2024-2030
France precision oncology market, 2018-2030 (US$M)
Related Markets
France precision oncology market highlights
- The France precision oncology market generated a revenue of USD 4,637.3 million in 2024 and is expected to reach USD 8,891.1 million by 2030.
- The France market is expected to grow at a CAGR of 11.5% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
Precision oncology market data book summary
| Market revenue in 2024 | USD 4,637.3 million |
| Market revenue in 2030 | USD 8,891.1 million |
| Growth rate | 11.5% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, France accounted for 4.0% of the global precision oncology market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK precision oncology market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 8,891.1 million by 2030.
Therapeutics was the largest segment with a revenue share of 79.11% in 2024. Horizon Databook has segmented the France precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in France is expected to grow at the fastest CAGR over the forecast period. The France market is growing due to the expanding adoption of advanced nuclear medicine diagnostics that enable more precise detection and monitoring of cancers. For instance, in May 2024, Curium introduced PYLCLARI (Piflufolastat [18F]), an innovative PET tracer that marked a significant milestone in prostate cancer care.
This diagnostic tool helps identify PSMA-positive lesions in high-risk patients and localize recurrence in those with rising PSA levels. By improving diagnostic accuracy, PYLCLARI has enhanced treatment planning and patient outcomes, reinforcing the country’s leadership in precision oncology and driving growth in the adoption of cutting-edge radiopharmaceutical solutions.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France precision oncology market size, by product, 2018-2030 (US$M)
France Precision Oncology Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
